Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control
- PMID: 26315600
- PMCID: PMC4558490
- DOI: 10.1038/emm.2015.76
Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) causes high fever, cough, acute respiratory tract infection and multiorgan dysfunction that may eventually lead to the death of the infected individuals. MERS-CoV is thought to be transmitted to humans through dromedary camels. The occurrence of the virus was first reported in the Middle East and it subsequently spread to several parts of the world. Since 2012, about 1368 infections, including ~487 deaths, have been reported worldwide. Notably, the recent human-to-human 'superspreading' of MERS-CoV in hospitals in South Korea has raised a major global health concern. The fatality rate in MERS-CoV infection is four times higher compared with that of the closely related severe acute respiratory syndrome coronavirus infection. Currently, no drug has been clinically approved to control MERS-CoV infection. In this study, we highlight the potential drug targets that can be used to develop anti-MERS-CoV therapeutics.
Figures
Similar articles
-
Spread of Mutant Middle East Respiratory Syndrome Coronavirus with Reduced Affinity to Human CD26 during the South Korean Outbreak.mBio. 2016 Mar 1;7(2):e00019. doi: 10.1128/mBio.00019-16. mBio. 2016. PMID: 26933050 Free PMC article.
-
Ca2+ Ions Promote Fusion of Middle East Respiratory Syndrome Coronavirus with Host Cells and Increase Infectivity.J Virol. 2020 Jun 16;94(13):e00426-20. doi: 10.1128/JVI.00426-20. Print 2020 Jun 16. J Virol. 2020. PMID: 32295925 Free PMC article.
-
Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.J Virol. 2016 Sep 12;90(19):8924-33. doi: 10.1128/JVI.01429-16. Print 2016 Oct 1. J Virol. 2016. PMID: 27466418 Free PMC article.
-
[Development of peptidic MERS-CoV entry inhibitors].Yao Xue Xue Bao. 2015 Dec;50(12):1513-9. Yao Xue Xue Bao. 2015. PMID: 27169270 Review. Chinese.
-
Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein.Virus Res. 2014 Dec 19;194:200-10. doi: 10.1016/j.virusres.2014.10.007. Epub 2014 Oct 14. Virus Res. 2014. PMID: 25451066 Free PMC article. Review.
Cited by
-
Design of novel multiepitope constructs-based peptide vaccine against the structural S, N and M proteins of human COVID-19 using immunoinformatics analysis.PLoS One. 2020 Oct 15;15(10):e0240577. doi: 10.1371/journal.pone.0240577. eCollection 2020. PLoS One. 2020. PMID: 33057358 Free PMC article.
-
Inhibition of SARS-CoV-2 3CL protease by the anti-viral chimeric protein RetroMAD1.Sci Rep. 2023 Nov 17;13(1):20178. doi: 10.1038/s41598-023-47511-z. Sci Rep. 2023. PMID: 37978223 Free PMC article.
-
Association between the expression of toll-like receptors, cytokines, and homeostatic chemokines in SARS-CoV-2 infection and COVID-19 severity.Heliyon. 2023 Jan;9(1):e12653. doi: 10.1016/j.heliyon.2022.e12653. Epub 2022 Dec 24. Heliyon. 2023. PMID: 36589720 Free PMC article.
-
Comparative overview of emerging RNA viruses: Epidemiology, pathogenesis, diagnosis and current treatment.Ann Med Surg (Lond). 2022 Jul;79:103985. doi: 10.1016/j.amsu.2022.103985. Epub 2022 Jun 11. Ann Med Surg (Lond). 2022. PMID: 35721786 Free PMC article. Review.
-
Middle East Respiratory Syndrome Virus Pathogenesis.Semin Respir Crit Care Med. 2016 Aug;37(4):572-7. doi: 10.1055/s-0036-1584796. Epub 2016 Aug 3. Semin Respir Crit Care Med. 2016. PMID: 27486737 Free PMC article. Review.
References
-
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources